June 5 (Reuters) - Danish drug developer Novo Nordisk said on Monday it had started talks to buy a controlling stake in French medical device designer Biocorp (ALCOR.PA). The price represents a premium of 19.5% over Biocorp's closing market price on June 2 and the transaction values Biocorp at about 154 million euros, the companies said. Certain minority shareholders, representing 19.0% of the share capital of Biocorp, will also transfer shares to Novo Nordisk and the transaction will be followed by a squeeze-out procedure. The block purchase should take place during the third quarter of 2023 and the filing of the subsequent offer should take place in September 2023, Novo said. ($1 = 0.9349 euros)Reporting by Michal Aleksandrowicz in Gdansk; Editing by Kim CoghillOur Standards: The Thomson Reuters Trust Principles.

---

Persons: Biocorp, Novo, Michal Aleksandrowicz, Kim Coghill Organizations: Novo Nordisk, Thomson Locations: Danish, Biocorp, Gdansk